Metraipolis › archive › dc_e1dcc0f4d680

Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post-Progression Outcomes: A Multicenter Real-World Study in Advanced Hepatocellular… — Europe PMC PMID:41704221

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41704221
DOI
10.1002/cam4.71655
License (as archived)
solo-consultazione
Archived
2026-11-06T08:55:54.156Z
SHA-256 of the archived text
f238513b5d19b53d78723e232ea26ffd22419cb7d3e2b421151e4bb8e668131f
Stable URL of this page
https://metraipolis.com/documento/dc_e1dcc0f4d680

How to cite

Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post-Progression Outcomes: A Multicenter Real-World Study in Advanced Hepatocellular… — Europe PMC PMID:41704221 — Europe PMC (en), https://europepmc.org/article/MED/41704221 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e1dcc0f4d680 (Metraipolis archive dc_e1dcc0f4d680, sha256 f238513b5d19b53d78723e232ea26ffd22419cb7d3e2b421151e4bb8e668131f)
BibTeX
@misc{dce1dcc0f4d680,
  title = {Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post-Progression Outcomes: A Multicenter Real-World Study in Advanced Hepatocellular… — Europe PMC PMID:41704221},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41704221},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e1dcc0f4d680; sha256 f238513b5d19b53d78723e232ea26ffd22419cb7d3e2b421151e4bb8e668131f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41704221. Agents can read the archived copy with the MCP tool read_document.